Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Artiva Biotherapeutics, Inc.
NASDAQ:ARTVHealthcare · Biotechnology
-0.95%$4.19
AH$4.19+0.00%vs close
Mkt Cap$204.85M
Float–
O/S48.89M
Vol
$ Vol
RVOL
Inst Own82.6%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$83.86M
Total Assets$130.94M
Free Cash Flow-$79.34M
Debt & Equity
Debt 9%
Equity 91%
Total Debt$10.94M
Total Equity$109.97M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ARTV's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$130.94M
Liabilities$20.97M
Accounts Receivable$767K
Accounts Payable$355K
Inventory$0
PP&E (Net)$17.36M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $251K | $33.49M | $4.93M | $2M | $0 |
| YoY Growth | - | -99.3% | 579.2% | 146.3% | - | - |
| Cost of Revenue | $2.6M | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | -$2.6M | $251K | $33.49M | $4.93M | $2M | $0 |
| Gross Margin | - | 100.0% | 100.0% | 100.0% | 100.0% | - |
| Research and Development | $69.54M | $50.33M | $50.25M | $43.98M | $42.41M | $13.85M |
| Selling, General, and Administrative | $20.27M | $17.2M | $13.91M | $20.78M | $12.86M | $4.43M |
| Other | -$1.8M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $88.01M | $67.53M | $64.16M | $64.76M | $55.27M | $18.27M |
| Operating Income (EBIT) | -$90.61M | -$67.28M | -$30.67M | -$59.83M | -$53.27M | -$18.27M |
| Operating Margin | - | -26805.6% | -91.6% | -1213.3% | -2660.9% | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $199K |
| Interest Income | $5.96M | $5.35M | $2.54M | $1.29M | $0 | $2K |
| Other Income (Expense) | $6.75M | $8.79M | $3.05M | $1.49M | -$18.55M | $280K |
| Income Before Tax (EBT) | -$83.86M | -$58.49M | -$27.62M | -$58.34M | -$71.83M | -$17.99M |
| Income Tax Expense | $0 | $0 | $72K | $53K | $0 | $0 |
| Net Income | -$83.86M | -$58.49M | -$27.7M | -$58.39M | -$71.83M | -$17.99M |
| Net Income Margin | - | -23304.0% | -82.7% | -1184.1% | -3587.7% | - |
| Supplementary Data | ||||||
| EPS | -3.43 | -5.20 | -1.19 | -3.32 | -4.08 | -1.02 |
| Diluted EPS | -3.43 | -5.20 | -1.19 | -3.32 | -4.08 | -1.02 |
| Weighted Average OS | 24.44M | 24.36M | 23.28M | 17.58M | 17.58M | 17.58M |
| EBITDA | -$81.27M | -$56.06M | -$25.36M | -$57.18M | -$71.58M | -$17.52M |
| EBITDA Margin | - | -22335.5% | -75.7% | -1159.5% | -3575.3% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $26.7M | $40.23M | $53.5M | $102.53M | $160.92M | $25.44M | $1.87M |
| Short-Term Investments | $81.31M | $145.19M | $23.47M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $108.01M | $185.43M | $76.97M | $102.53M | $160.92M | $25.44M | $1.87M |
| Accounts Receivable | $767K | $146K | $1.76M | $525K | $468K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.89M | $3.06M | $1.09M | $1.62M | $0 | $0 | $0 |
| Total Current Assets | $112.67M | $188.63M | $79.82M | $104.67M | $162.29M | $26.11M | $1.96M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $17.36M | $20.43M | $24.64M | $27.62M | $4.08M | $2.39M | $2.5M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $245K | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $919K | $525K | $650K | $517K | $3.56M | $732K | $377K |
| Total Long-Term Assets | $18.27M | $20.95M | $25.29M | $28.38M | $7.64M | $3.13M | $2.88M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $130.94M | $209.58M | $105.11M | $133.05M | $169.93M | $29.23M | $4.84M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $355K | $1.12M | $614K | $1.1M | $1.44M | $2.15M | $258K |
| Short-Term Debt | $3.06M | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $10.89M | $7.29M | $0 | $0 |
| Other Current Liabilities | $2.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $13.09M | $12.25M | $12.23M | $25.63M | $19.3M | $5.76M | $942K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $7.88M | $0 | $0 | $0 | $0 | $0 | $5.64M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $15.63M | $21.68M | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $216.41M | $216.41M | $0 | $0 |
| Other Long-Term Liabilities | $0 | $73K | $241.59M | $115K | $81K | $43.38M | $245K |
| Total Long-Term Liabilities | $7.88M | $10.69M | $254.9M | $248.13M | $239.48M | $45.04M | $7.86M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $20.97M | $22.94M | $267.13M | $273.75M | $258.78M | $50.8M | $8.8M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $3K | $3K | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$330.55M | -$246.68M | -$181.31M | -$152.59M | -$93.8M | -$21.98M | -$3.99M |
| Comprehensive Income & Other | $103K | -$129K | $308K | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $440.52M | $433.32M | $19.3M | $11.89M | $4.95M | $411K | $27K |
| Total Equity | $109.97M | $186.64M | -$162.01M | -$140.7M | -$88.86M | -$21.57M | -$3.96M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $130.94M | $209.58M | $105.11M | $133.05M | $169.93M | $29.23M | $4.84M |
| Supplementary Data | |||||||
| Total Debt | $10.94M | $14.35M | $16.91M | $19.45M | $1.74M | $2.12M | $7.82M |
| Net Debt | -$15.76M | -$25.88M | -$36.59M | -$83.08M | -$159.18M | -$23.33M | $5.95M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$83.86M | -$65.37M | -$28.72M | -$58.79M | -$71.83M | -$17.99M |
| Depreciation & Amortization | $2.6M | $2.43M | $2.27M | $1.16M | $248K | $73K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $6.82M | $6.98M | $7.05M | $6.58M | $4.31M | $297K |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $79K | $1.61M | -$1.23M | -$57K | -$468K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$760K | $519K | -$408K | $190K | -$1.24M | $1.82M |
| Other Working Capital | $257K | -$2.46M | -$26.64M | -$4M | $35.13M | $2.54M |
| Total Working Capital Change | -$424K | -$325K | -$28.28M | -$3.87M | $33.41M | $4.36M |
| Other Non-Cash Items | -$1.88M | $1.25M | $251K | $4.08M | $18.55M | -$278K |
| Net Cash from Operating | -$76.75M | -$55.03M | -$47.43M | -$50.83M | -$15.3M | -$13.54M |
| Investing Activities | ||||||
| Capital Expenditures | -$2.59M | -$642K | -$3.26M | -$6.3M | -$1.72M | -$284K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$44.88M | -$176.17M | -$49.52M | $0 | $0 | $0 |
| Sales of Investments | $110.87M | $56.35M | $26.8M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $63.41M | -$120.46M | -$25.98M | -$6.3M | -$1.72M | -$284K |
| Financing Activities | ||||||
| Debt Repaid | $132K | $149K | - | - | - | -$3M |
| Common Stock Issuance | $371K | $166.51M | $0 | $0 | $0 | $215K |
| Common Stock Repurchases | $0 | -$4.18M | -$12K | -$5K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$230K | $51K | $24.4M | -$1.26M | -$1.86M | -$459K |
| Net Cash from Financing | $9K | $162.23M | $24.39M | -$1.26M | $152.75M | $37.4M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$13.33M | -$13.27M | -$49.01M | -$58.39M | $135.73M | $23.57M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$76.75M | -$55.03M | -$47.43M | -$50.83M | -$15.3M | -$13.54M |
| Capital Expenditure | -$2.59M | -$642K | -$3.26M | -$6.3M | -$1.72M | -$284K |
| Free Cash Flow | -$79.34M | -$55.67M | -$50.69M | -$57.13M | -$17.03M | -$13.82M |
| Cash at Beginning | $40.49M | $53.76M | $102.78M | $161.17M | $25.44M | $1.87M |
| Cash at End | $27.16M | $40.49M | $53.76M | $102.78M | $161.17M | $25.44M |